TABLE 1.
The description and purpose of used datasets in the present study
| Dataset |
Available sample size T/N |
PMID | Description | Purpose |
|---|---|---|---|---|
| TCGA | 537/72 | — | KIRC project |
1. Expression analysis 2. Training cohort of prognostic value |
| ICGC | 91/0 | — | RECA‐EU project |
1. Expression analysis 2. Validation cohort of prognostic value |
| GSE29609 | 39/0 | 22626276 | Whole genome expression and clinical characteristics of ccRCC patients | Validation cohort of prognostic value |
| GSE53757 | 73/73 | 24962026 | Gene expression profile of RCC and matched normal renal tissues | Expression analysis |
| GSE66271 | 13/13 | 26859141 | Gene expression profile of mRCC and matched normal renal tissues | Expression analysis |
| GSE168845 | 4/4 | NA | Gene expression profile of RCC (stages III–IV) and matched normal renal tissues | Expression analysis |
| GSE15641 | 45/23 | 16115910 | Transcriptional profiling of ccRCC, pRCC, chrRCC, RO, and normal samples | Expression analysis |
| GSE105261 | 35/9 | 30131446 | Transcriptional profiling of primary RCC, mRCC, and normal samples | Expression analysis |
| GSE150404 | 60/0 | NA | Expression data from RCC patients with different stages | Expression analysis |
| GSE87121 | 10/0 | NA | Expression data in RCC samples from patients who presented sorafenib resistance or effective | Therapeutic correlation |
| GSE67501 | 11/0 | 27491898 | Expression data in RCC samples from patients who did or did not respond to nivolumab | Therapeutic correlation |
Abbreviations: ccRCC, clear cell renal cell carcinoma; chrRCC, chromophobe RCC; EU, Europe; KIRC, kidney renal clear cell carcinoma; mRCC, metastatic RCC; NA, not available; pRCC, papillary RCC; RECA, renal cell cancer; RO, renal oncocytoma; T/N, Tumor samples versus normal samples.